MDR-Chin研究解析:耐多药肺结核全口服短程治疗方案在中国的应用前景
MDR-Chin study analysis:prospects of using all-oral short-course treatment regimens for multidrug-resistant pulmonary tuberculosis in China
摘要
Abstract
The global trend in the treatment of multidrug-resistant tuberculosis(MDR-TB)is to shorter treatment durations.The MDR-Chin study is China's first cohort study to explore all-oral short-course regimens for the treatment of MDR-TB and pre-extensive drug-resistant tuberculosis(pre-XDR-TB),validating the efficacy and safety of three different treatment regimens.The results indicated that within a 12-month follow-up after the drug withdrawal,96％of MDR-TB patients and 83.3％of pre-XDR-TB patients achieved favorable outcomes;the overall rate of favorable outcomes was 92.9％.Although grade 3 or higher adverse events(AEs)were quite common(48.1％),most were manageable and controllable,with relatively rare serious AEs(7.7％).In the study,loss-to-follow-up rate was low,the advantages of the all-oral short-course regimen were reflected and the potential for application in resource-limited settings was displayed.In this article,the author provides an overview of the MDR-Chin study,analyzesthe advantages and disadvantages,and discusses the application and future directions of clinical research for all-oral,short-course treatment regimens in China.关键词
结核,肺/抗药性,多药/临床方案/治疗应用Key words
Tuberculosis,pulmonary/Drug resistance,multiple/Clinical protocols/Therapeutic uses分类
医药卫生引用本文复制引用
付亮,邓国防..MDR-Chin研究解析:耐多药肺结核全口服短程治疗方案在中国的应用前景[J].中国防痨杂志,2024,46(1):18-22,5.基金项目
National Natural Science Foundation of China(82070016) （82070016）
Guangdong Provincial Clinical Research Center for Tuberculosis Project(2020B1111170014) （2020B1111170014）
Shenzhen Clinical Research Center for Tuberculosis(20210617141509001) （20210617141509001）
Summit Plan for Foshan High-Level Hospital Construction(FSSYKF-2020001005597) （FSSYKF-2020001005597）
Foshan Science and Technology Innovation Plan(2020001005597) （2020001005597）
Shenzhen Third People's Hospital(grant number G2021023,G2022155)国家自然科学基金(82070016) （grant number G2021023,G2022155）
广东省结核病临床研究中心(2020B1111170014) （2020B1111170014）
深圳市结核病临床研究中心(20210617141509001) （20210617141509001）
佛山市开放课题(FSSYKF-2020001005597) （FSSYKF-2020001005597）
佛山市科技创新计划(2020001005597) （2020001005597）
深圳市第三人民医院课题(G2021023,G2022155) （G2021023,G2022155）
